Renal Cancer - Results from #1600

Identifying Early Predictive Markers for Immune-Related Adverse Events in Nivolumab-Treated Patients with Renal Cell Carcinoma and Gastric Cancer. March 2, 2022

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. March 1, 2022

Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives. March 1, 2022

Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review. February 28, 2022

Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies. February 28, 2022

PDE4D targeting enhances anti-tumor effects of sorafenib in clear cell renal cell carcinoma and attenuates MAPK/ERK signaling in a CRAF-dependent manner. February 25, 2022

Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. February 25, 2022

Robotic partial nephrectomy in 3D virtual reconstructions era: is the paradigm changed? February 24, 2022

Exploration of Prognostic Immune-Related Genes and lncRNAs Biomarkers in Kidney Renal Clear Cell Carcinoma and Its Crosstalk with Acute Kidney Injury. February 24, 2022

Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma. February 23, 2022

Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. February 23, 2022

Investigating Urinary Circular RNA Biomarkers for Improved Detection of Renal Cell Carcinoma. February 22, 2022

External validation of the VENUSS prognostic model to predict recurrence after surgery in non-metastatic papillary renal cell carcinoma: A multi-institutional analysis. February 22, 2022

The prognostic impact of Claudin 6 in papillary renal cell carcinoma. February 21, 2022

First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been? February 21, 2022

Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma. February 21, 2022

Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. February 18, 2022

Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial. February 18, 2022

Renal Cell Carcinoma Surgical Treatment Disparities in American Indian/Alaska Natives and Hispanic Americans in Arizona. February 17, 2022

The Next Paradigm Shift in the Management of Clear Cell Renal Cancer: Radiogenomics-Definition, Current Advances, and Future Directions. February 17, 2022

Page 81 of 456